LNP ©NCI/Adapted from Vaccines. January 2021. https://doi.org/10.3390/vaccines9010065. CC BY 4.0.

Moderna co-founder Kenneth Chien and Novalis LifeSciences LLC are the lead investors of a €39m Series B2 financing in eTheRNA.

A fundus photo showing intermediate age-related macular degeneration. © National Eye Institute, National Institutes of Health

Kinarus Therapeutics Holding AG has raised US$20m in financing through the issuance of convertible bonds to YA II PN, Ltd.

Pixabay.com

A study in the scientific journal The Lancet shows that half of all global cancer deaths are due to life style-related risk factors such as smoking and alcohol use.

Ryvu Therapeutics' R&D centre at Krakow. © Ryvu Therapeutics

Polish cancer drug developer, Ryvu Therapeutics, has received €22m funding from the European Investment Bank via its venture debt instrument.

©Avantium NV

Avantium and AmBev, part of AB InBev Group, have inked an agreement on PEF for soft drink bottles.

SHREAD-transduced cells (blue), expressed trastuzumab (yellow), and tumour vasculature (red). © PNAS, 10.1073/pnas.201792511

With a Series A funding of CHF 30m from Versant Ventures, Vector Biopharma AG set out to solve several of the current gene delivery problems.

© Novartis/AveXis

Swiss-headquarterd Novartis AG has reported two cases of fatal liver failure after treatment with the gene therapy Zolgensma.

© B Medical Systems

Azenta Inc has entered into an agreement to acquire B Medical Systems S.á r.l. and its subsidiaries for  €410m.

© Albumedix Ltd

Sartorius Stedim Biotech has purchased the world’s largest human albumin producer Albumedix to broaden its product portfolio in animal-free cell media and to stabilise protein drugs.

Hexabody binding to the surface of a T cell. © Genmab A/S

As Genmab’s Hexabody tumour antibody platform is advancing, BioNTech has secured a licence in the field of immunotherapy to co-develop antibodies on 50:50 base.